Gilead Sciences has received permission from the Food and Drug Administration for an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy (bictegravir 50 ...

The Food and Drug Administration has given Gilead the green light for a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for ...

FDA recently approved a new low-dose tablet dosage form of Gilead’s HIV-1 drug, Biktarvy, in pediatric patients. The agency approved the new dosage for children weighing at least 30 pounds who are ...

No new safety or tolerability concerns were observed with Biktarvy during pregnancy and postpartum. The Food and Drug Administration (FDA) has approved updated labeling for Biktarvy ® (bictegravir ...

(RTTNews) - Gilead Sciences, Inc. (GILD) announced the FDA approved a new low-dose tablet dosage form of Biktarvy for pediatric patients weighing at least 14 kg to less than 25 kg who are ...

The low-dose tablet will help pediatric patients weighing between 14 kg and 25 kg who are virologically suppressed or new to antiretroviral therapy. Gilead Sciences, Inc announced Monday the FDA ...

Please provide your email address to receive an email when new articles are posted on . Gilead Sciences said the FDA has approved a new low-dose tablet form of its HIV drug Biktarvy for pediatric ...

Taking Biktarvy with NSAIDs, such as ibuprofen, may increase the risk of kidney problems, including acute kidney failure. Antacids containing aluminum or magnesium may make Biktarvy less effective. If ...

– Perinatal Guidelines Recognize Biktarvy as Alternative Regimen for Use During Pregnancy and for Those Trying to Conceive – The updated label now includes additional data from Study 5310, a Phase 1b, ...